Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 May 9;13(10):2785.
doi: 10.3390/jcm13102785.

Bilateral Atypical Femoral Fracture in a Bisphosphonate-Naïve Patient with Prior Long-Term Denosumab Therapy: A Case Report of the Management Strategy and a Literature Review

Affiliations
Case Reports

Bilateral Atypical Femoral Fracture in a Bisphosphonate-Naïve Patient with Prior Long-Term Denosumab Therapy: A Case Report of the Management Strategy and a Literature Review

Kyle Auger et al. J Clin Med. .

Abstract

The benefits of denosumab as an antiresorptive therapy and in reducing fragility fractures are well documented. However, its association with atypical femur fractures (AFFs), especially in the absence of prior bisphosphonate use, remains poorly understood and warrants further investigation. This case report presents a rare instance of bilateral AFFs in a 78-year-old bisphosphonate-naïve patient with a history of long-term denosumab therapy for previous metastatic breast cancer. Management involved intramedullary nail fixation after initial presentation with a unilateral AFF and a recommendation to cease denosumab therapy. However, the patient subsequently experienced a contralateral periprosthetic AFF below a total hip implant 5 months thereafter and was treated with open reduction internal fixation. This case report highlights the critical need for orthopedic surgeons to maintain a high level of suspicion and vigilance in screening for impending AFFs, especially in patients with a prolonged history of denosumab therapy without prior bisphosphonate use. Furthermore, the growing report of such cases emphasizes the urgent need for comprehensive research aimed at refining treatment protocols that balance the therapeutic benefits of denosumab and its associated risks of AFFs.

Keywords: atypical femoral fracture; bisphosphonate; bone antiresorptive therapy; denosumab; subtrochanteric fracture.

PubMed Disclaimer

Conflict of interest statement

The authors declare no direct conflicts of interest in connection with the submitted article. However, interests that may be perceived as influencing the representation or interpretation of the reported research results are reported by authors.: I.S.H.: Foundation for Orthopedic Trauma: Research support; Irrimax Corporation: Research support; LifeNet Health: Paid consultant. F.A.L.: AAOS: Board or committee member; AO: Unpaid consultant; Biomet: IP royalties, Paid consultant, Paid presenter or speaker, Research support; DePuy, A Johnson & Johnson Company: IP royalties, Research support; Orthopedic Trauma Association: Board or committee member; Stryker: IP royalties; Synthes: Paid consultant; Paid presenter or speaker. R.S.Y.: American Association of Hip and Knee Surgeons: Board or committee member; AO Foundation: Research support; AO Innovation Translation Center: Research support; Arthrex, Inc: IP royalties, Paid consultant; Bicomposites: Research support; Biomet: Research support; COTA: Research support; DePuy, A Johnson & Johnson Company: Paid consultant, Research support; Foundation for Physician Advancement: Board or committee member; Foundation for Orthopedic Trauma: Board or committee member; Irrimax: Research support; MiCare Health: Paid consultant; OMEGA: Research support; Organogenesis: Research support; ORintelligence: Stock or stock Options; OrthoGrid: Paid consultant; Orthopedic Trauma Association: Board or committee member, ORTHOXEL: Paid consultant, Pacira: Research support; SI-Bone: Paid consultant, Research support; Springer: Publishing royalties, financial or material support; Stryker: IP royalties; Paid consultant; Synthes: Paid consultant; Research support, Use-Lab: Paid consultant; WNT Scientific: Stock or stock Options.

Figures

Figure 1
Figure 1
Radiographs demonstrating a transverse left subtrochanteric femur fracture with a medial spike in a 78-year-old female patient.
Figure 2
Figure 2
Radiographs of contralateral right femur demonstrating lateral cortical thickening distal to stem of femoral implant in 78-year-old female patient.
Figure 3
Figure 3
(A)—Three-month postoperative radiographs of left femur demonstrating delayed healing of subtrochanteric fracture with stable intramedullary nail fixation (top). (B)—Radiographs of the contralateral femur demonstrating lateral cortical beaking and thickening distal to the previous hip prosthesis (bottom).
Figure 4
Figure 4
Radiographs demonstrating an acute atypical mid-shaft right periprosthetic femur fracture distal to the femoral stem (Vancouver Type C).
Figure 5
Figure 5
Immediate postoperative radiographs following open reduction and internal fixation with a lateral periprosthetic femoral plate.
Figure 6
Figure 6
Most recent follow-up radiographs demonstrating healing of both femur fractures with no evidence of hardware failure: (A)—approximately 10 months following left femur nonunion surgery (top) and (B)—2 years after right atypical periprosthetic femoral shaft fixation (bottom).

Similar articles

Cited by

References

    1. Yoon R.S., Hwang J.S., Beebe K.S. Long-Term Bisphosphonate Usage and Subtrochanteric Insufficiency Fractures: A Cause for Concern? J. Bone Jt. Surg. Br. Vol. 2011;93-B:1289–1295. doi: 10.1302/0301-620X.93B10.26924. - DOI - PubMed
    1. Shane E., Burr D., Abrahamsen B., Adler R.A., Brown T.D., Cheung A.M., Cosman F., Curtis J.R., Dell R., Dempster D.W., et al. Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research. J. Bone Miner. Res. 2014;29:1–23. doi: 10.1002/jbmr.1998. - DOI - PubMed
    1. Starr J., Tay Y.K.D., Shane E. Current Understanding of Epidemiology, Pathophysiology, and Management of Atypical Femur Fractures. Curr. Osteoporos. Rep. 2018;16:519–529. doi: 10.1007/s11914-018-0464-6. - DOI - PMC - PubMed
    1. Takahashi M., Ozaki Y., Kizawa R., Masuda J., Sakamaki K., Kinowaki K., Umezu T., Kondoh C., Tanabe Y., Tamura N., et al. Atypical Femoral Fracture in Patients with Bone Metastasis Receiving Denosumab Therapy: A Retrospective Study and Systematic Review. BMC Cancer. 2019;19:980. doi: 10.1186/s12885-019-6236-6. - DOI - PMC - PubMed
    1. Ota S., Inoue R., Shiozaki T., Yamamoto Y., Hashimoto N., Takeda O., Yoshikawa K., Ito J., Ishibashi Y. Atypical Femoral Fracture after Receiving Antiresorptive Drugs in Breast Cancer Patients with Bone Metastasis. Breast Cancer. 2017;24:601–607. doi: 10.1007/s12282-016-0746-8. - DOI - PMC - PubMed

Publication types

LinkOut - more resources